C4 Therapeutics, Inc. (CCCC) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Company Overview - C4 Therapeutics is a targeted protein degradation company focused on developing medicines for areas of high unmet need [2] - The company currently has two programs in the clinic, with the most advanced being Cemsidomide, an IKZF1/3 degrader targeting multiple myeloma [2] Clinical Development - C4 Therapeutics completed a Phase I study for Cemsidomide last year and has initiated a Phase II study called MOMENTUM, which began dosing patients last month [2] - The company plans to start a Phase Ib study in Q2 in combination with elranatamab, a BiTE from Pfizer, indicating a differentiated registrational path for its development [3]